Image of a Nurse checking man’s blood glucose level using a fingerstick glucose meter. As per data presented at EASD 2026, at six months of use, tirzepatide showed greater effectiveness across concomitant glucose-lowering therapy groups, with the greatest benefits observed in patients receiving no additional treatment, suggesting potential benefits from earlier initiation in type 2 diabetes care. Image credit: Shutterstock/[Halfpoint]

Unlock FREE Access to Premium Content

​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends.

With a free Pharmaceutical Technology profile, you can:

  • Access exclusive analyst commentary and expert insights
  • View premium forecasts and data-driven pharmaceutical industry insights
  • Stay up to date with pharma news, manufacturing innovation, and regulatory developments
  • Receive alerts when new premium content is published
Unlock free access
Already have an account? Login here

Powered by